Skip to content

GLP-1 Receptor Agonist Use before Total Knee Arthroplasty is Associated with Lower Postoperative MI, DVT, and VTE Rates

Mar 2026 · The journal of knee surgery · 0 citations · 24 references
Medicine

Abstract

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for glycemic control and weight management, but their association with postoperative thrombotic events after total knee arthroplasty (TKA) remains unclear. We performed a retrospective cohort study using de-identified data from the TriNetX United States Collaborative Network, including adults who underwent primary TKA between December 1, 2006, and June 1, 2025. Patients with prior myocardial infarction (MI), deep vein thrombosis (DVT), venous thromboembolism (VTE), or pulmonary embolism (PE) were excluded. Exposure was defined as a prescription for a GLP-1 RA within 1 year and 1 day before surgery. A 1:1 propensity score match was performed on demographics, relevant comorbidities, and medications, yielding 11,765 patients in each cohort. Outcomes were postoperative MI, DVT, VTE, and PE. Compared with matched controls, patients prescribed GLP-1 RAs had a significantly lower risk of MI (25/11,246 vs. 47/11,171; risk ratio [RR] 0.528; 95% confidence interval [CI], 0.325–0.858). GLP-1 RAs use was also associated with a reduced risk of DVT (74/11,319 vs. 103/11,308; RR 0.718; 95% CI, 0.533–0.966) and VTE (133/11,040 vs. 172/11,027; RR 0.772; 95% CI, 0.617–0.967). In contrast, no statistically significant difference was observed in the incidence of PE between groups (49/11,352 vs. 58/11,382; RR 0.847; 95% CI, 0.580–1.238). Overall, preoperative GLP-1 RA use was associated with a significantly lower postoperative risk of MI, DVT, and VTE following TKA in this large, nationally representative cohort.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.